首页 | 本学科首页   官方微博 | 高级检索  
     


Sequences in Glycoprotein gp41, the CD4 Binding Site,and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies
Authors:Sara M. O'Rourke  Becky Schweighardt  Pham Phung  Kathryn A. Mesa  Aaron L. Vollrath  Gwen P. Tatsuno  Briana To  Faruk Sinangil  Kay Limoli  Terri Wrin  Phillip W. Berman
Affiliation:aDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, USA;bMonogram Biosciences, South San Francisco, California, USA;cGlobal Solutions for Infectious Diseases, South San Francisco, California, USA
Abstract:The swarm of quasispecies that evolves in each HIV-1-infected individual represents a source of closely related Env protein variants that can be used to explore various aspects of HIV-1 biology. In this study, we made use of these variants to identify mutations that confer sensitivity and resistance to the broadly neutralizing antibodies found in the sera of selected HIV-1-infected individuals. For these studies, libraries of Env proteins were cloned from infected subjects and screened for infectivity and neutralization sensitivity. The nucleotide sequences of the Env proteins were then compared for pairs of neutralization-sensitive and -resistant viruses. In vitro mutagenesis was used to identify the specific amino acids responsible for the neutralization phenotype. All of the mutations altering neutralization sensitivity/resistance appeared to induce conformational changes that simultaneously enhanced the exposure of two or more epitopes located in different regions of gp160. These mutations appeared to occur at unique positions required to maintain the quaternary structure of the gp160 trimer, as well as conformational masking of epitopes targeted by neutralizing antibodies. Our results show that sequences in gp41, the CD4 binding site, and the V2 domain all have the ability to act as global regulators of neutralization sensitivity. Our results also suggest that neutralization assays designed to support the development of vaccines and therapeutics targeting the HIV-1 Env protein should consider virus variation within individuals as well as virus variation between individuals.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号